Vaccinex will present positive clinical results of neoadjuvant treatment with pepinemab at ASCO Annual Meeting. Enhanced immunotherapy in head and neck cancer patients.

Pepinemab, when used as neoadjuvant treatment, has shown to stimulate the development of plentiful and mature lymphoid structures, which have been linked to enhanced pathologic response. The findings suggest that neoadjuvant treatment with pepinemab results in the formation of increased mature lymphoid structures that are associated with better pathologic response.